Insider transactions

EDGAR

HAEMONETICS CORPORATION

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
1 transactions, 836 shares
Sum of shares × price per share: 101,147.64

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–34 of 34

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,06889.16
95,222.88

Derived: shares × price per share. Exact value 95222.88.

7,310Direct (D) No
F1
  • F1 This number includes unvested restricted stock units (RSUs) previously reported.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)64595.73
61,745.85

Derived: shares × price per share. Exact value 61745.85.

7,955Direct (D) No
F1
  • F1 This number includes unvested restricted stock units (RSUs) previously reported.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)43370.31
30,444.23

Derived: shares × price per share. Exact value 30444.23.

8,388Direct (D) No
F1
  • F1 This number includes unvested restricted stock units (RSUs) previously reported.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,724121.10
208,776.4

Derived: shares × price per share. Exact value 208776.40.

6,664Direct (D) No
F2, F1
  • F2 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
  • F1 This number includes unvested restricted stock units (RSUs) previously reported.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)836120.99
101,147.64

Derived: shares × price per share. Exact value 101147.64.

5,828Direct (D) No
F3, F1
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation (Haemonetics), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  • F1 This number includes unvested restricted stock units (RSUs) previously reported.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-qualified Stock Option (Right to Buy) — underlying Common Stock (1,068) — exercise price 89.16
Disposed (D)1,0680—357Direct (D) No
F4
  • F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-qualified Stock Option (Right to Buy) — underlying Common Stock (645) — exercise price 95.73
Disposed (D)6450—646Direct (D) No
F4
  • F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Non-qualified Stock Option (Right to Buy) — underlying Common Stock (433) — exercise price 70.31
Disposed (D)4330—1,299Direct (D) No
F4
  • F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Open filing 0000313143-26-000155 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03Galvin Roy Officer: EVP, Chief Commercial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)146119.65
17,468.9

Derived: shares × price per share. Exact value 17468.90.

39,805Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported as well as 69 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on October 31, 2026.
Open filing 0000313143-26-000144 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28KROLL MARK W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——27,295Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000107 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28ABERNATHY ROBERT E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——27,519Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000099 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Madaus Martin D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——2,538Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000112 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Johnson Lloyd Emerson Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——15,471Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000105 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28COYLE MICHAEL J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——17,932Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000103 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Bryant Diane M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——9,664Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000101 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Zane Ellen M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——21,911Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000111 Read from the filing’s XML Dispute this row
2026-07-24 Filed 2026-07-28Pomeroy Claire Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,538——19,410Direct (D) No
F1, F2
  • F1 The securities awarded are in the form of restricted stock units (RSUs) issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
  • F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Open filing 0000313143-26-000109 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-08Miller Laurie A. Officer: SVP, Human Resources
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)31371.28
22,310.64

Derived: shares × price per share. Exact value 22310.64.

40,987Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000066 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-08Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)25971.28
18,461.52

Derived: shares × price per share. Exact value 18461.52.

6,242Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000068 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Miller Laurie A. Officer: SVP, Human Resources
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)94856.29
53,362.92

Derived: shares × price per share. Exact value 53362.92.

27,977Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000043 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Miller Laurie A. Officer: SVP, Human Resources
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,323——41,300Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000043 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Galvin Roy Officer: EVP, Chief Commercial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)87956.29
49,478.91

Derived: shares × price per share. Exact value 49478.91.

12,347Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
Open filing 0000313143-26-000044 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Galvin Roy Officer: EVP, Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)27,535——39,882Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported as well as 415 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
Open filing 0000313143-26-000044 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Chan Frank Officer: EVP, Chief Operating Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)54656.29
30,734.34

Derived: shares × price per share. Exact value 30734.34.

5,401Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the ESPP) and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.
Open filing 0000313143-26-000047 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Chan Frank Officer: EVP, Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)27,535——32,936Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the ESPP) and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.
Open filing 0000313143-26-000047 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19DArecca James Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,50556.29
141,006.45

Derived: shares × price per share. Exact value 141006.45.

25,132Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000046 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19DArecca James Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)29,312——54,444Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000046 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Basil Michelle L Officer: EVP and General Counsel
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,91356.29
163,972.77

Derived: shares × price per share. Exact value 163972.77.

40,405Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000048 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Basil Michelle L Officer: EVP and General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)28,424——68,829Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000048 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Simon, Christopher Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)9,68156.29
544,943.49

Derived: shares × price per share. Exact value 544943.49.

366,360Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
Open filing 0000313143-26-000042 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Simon, Christopher Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)78,344——444,704Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
Open filing 0000313143-26-000042 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)19756.29
11,089.13

Derived: shares × price per share. Exact value 11089.13.

4,281Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000045 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-19Maunsell Farris Maryanne Officer: VP, Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,220——6,501Direct (D) No
F3, F4, F2
  • F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
  • F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000045 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-05DArecca James Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)65559.26
38,815.3

Derived: shares × price per share. Exact value 38815.30.

27,637Direct (D) No
F1, F2
  • F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (RSUs) previously reported in Table I.
  • F2 This number includes unvested RSUs previously reported.
Open filing 0000313143-26-000026 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 430

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Linden Advisors LP 131,324,000 PRN149,520,610 dollarsLower by 45,587,000 Prior quarter: 176,911,000Open filing 0001193125-26-462390 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager77,850,000 PRN88,441,493 dollarsHigher by 16,450,000 Prior quarter: 61,400,000Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Invesco Ltd. Partly reported under another manager61,696,000 PRN70,089,741 dollarsHigher by 2,500,000 Prior quarter: 59,196,000Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
VOYA INVESTMENT MANAGEMENT LLC Partly reported under another manager37,335,000 PRN42,601,052 dollarsNot in the prior quarter’s filings read Open filing 0001068837-26-000006 Filed 2026-11-10 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager36,000,000 PRN45,378,000 dollarsUnchanged Prior quarter: 36,000,000Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Wellesley Asset Management 33,839,000 PRN36,415,402 dollarsLower by 4,044,000 Prior quarter: 37,883,000Open filing 0001533551-26-000009 Filed 2026-11-12 Dispute this row
ARES MANAGEMENT LLC Partly reported under another manager32,215,000 PRN36,735,087 dollarsHigher by 1,450,000 Prior quarter: 30,765,000Open filing 0001104659-26-128209 Filed 2026-11-16 Dispute this row
WOLVERINE ASSET MANAGEMENT LLC Partly reported under another manager25,000,000 PRN28,453,959 dollarsNot in the prior quarter’s filings read Open filing 0001279891-26-000016 Filed 2026-11-02 Dispute this row
Calamos Advisors LLC 23,911,000 PRN27,343,185 dollarsHigher by 13,911,000 Prior quarter: 10,000,000Open filing 0001316507-26-000004 Filed 2026-11-02 Dispute this row
Balyasny Asset Management L.P. 20,000,000 PRN22,845,886 dollarsHigher by 15,000,000 Prior quarter: 5,000,000Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
DeepCurrents Investment Group LLC Partly reported under another manager19,040,000 PRN21,678,462 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002696 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager16,932,000 PRN19,439,260 dollarsLower by 950,000 Prior quarter: 17,882,000Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
KIM, LLC Partly reported under another manager15,000,000 PRN17,085,030 dollarsLower by 5,000,000 Prior quarter: 20,000,000Open filing 0001888968-26-000006 Filed 2026-11-16 Dispute this row
SILVERBACK ASSET MANAGEMENT LLC 12,918,000 PRN14,726,520 dollarsLower by 1,365,000 Prior quarter: 14,283,000Open filing 0001398344-26-020122 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager12,762,000 PRN14,498,253 dollarsHigher by 2,140,000 Prior quarter: 10,622,000Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Lombard Odier Asset Management (Europe) Ltd 9,985,000 PRN11,500,762 dollarsUnchanged Prior quarter: 9,985,000Open filing 0000908834-26-000555 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager8,790,000 PRN9,985,881 dollarsUnchanged Prior quarter: 8,790,000Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Fore Capital, LLC Partly reported under another manager8,500,000 PRN9,698,914 dollarsHigher by 1,500,000 Prior quarter: 7,000,000Open filing 0001714672-26-000005 Filed 2026-11-13 Dispute this row
SSI INVESTMENT MANAGEMENT LLC Partly reported under another manager8,272,000 PRN9,397,394 dollarsHigher by 1,522,000 Prior quarter: 6,750,000Open filing 0001172661-26-004930 Filed 2026-11-10 Dispute this row
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main Partly reported under another manager7,717,000 PRN8,817,444 dollarsHigher by 267,000 Prior quarter: 7,450,000Open filing 0000905148-26-004847 Filed 2026-11-16 Dispute this row
Weiss Asset Management LP Partly reported under another manager6,500,000 PRN7,433,001 dollarsNot in the prior quarter’s filings read Open filing 0001357550-26-000042 Filed 2026-11-16 Dispute this row
Ares Systematic Credit Ltd 6,200,000 PRN7,074,502 dollarsHigher by 5,800,000 Prior quarter: 400,000Open filing 0001104659-26-128229 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager5,953,537 SH626,907,447 dollarsHigher by 44,279 Prior quarter: 5,909,258Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
CSS LLC/IL Partly reported under another manager5,500,000 PRN6,258,296 dollarsLower by 6,000,000 Prior quarter: 11,500,000Open filing 0001103646-26-000019 Filed 2026-11-16 Dispute this row
CAPSTONE INVESTMENT ADVISORS, LLC Partly reported under another manager5,150,000 PRN5,876,401 dollarsNot in the prior quarter’s filings read Open filing 0001426196-26-000006 Filed 2026-11-16 Dispute this row
Nykredit A/S Partly reported under another manager5,000,000 PRN5,745,419 dollarsUnchanged Prior quarter: 5,000,000Open filing 0001847328-26-000005 Filed 2026-11-06 Dispute this row
PICTON MAHONEY ASSET MANAGEMENT 5,000,000 PRN5,717,702 dollarsNot in the prior quarter’s filings read Open filing 0001539041-26-000039 Filed 2026-11-09 Dispute this row
Eubel Brady Suttman Asset Management Inc 5,000,000 PRN5,680 dollarsUnchanged Prior quarter: 5,000,000Open filing 0001080382-26-000012 Filed 2026-11-04 Dispute this row
STATE OF WISCONSIN INVESTMENT BOARD 4,075,290 SH12,472,237 dollarsHigher by 29,400 Prior quarter: 4,045,890Open filing 0001062993-26-006051 Filed 2026-11-16 Dispute this row
NEUBERGER BERMAN GROUP LLC 3,481,774 SH366,662,995 dollarsLower by 697,669 Prior quarter: 4,179,443Open filing 0001465109-26-000128 Filed 2026-11-13 Dispute this row
Fort Baker Capital Management LP 3,250,000 PRN3,743,572 dollarsLower by 16,000,000 Prior quarter: 19,250,000Open filing 0002085853-26-001392 Filed 2026-11-16 Dispute this row
INCOME RESEARCH MANAGEMENT 2,570,000 SH2,919,645 dollarsLower by 700,000 Prior quarter: 3,270,000Open filing 0001214659-26-013106 Filed 2026-10-21 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 2,501,221 SH263,378,571 dollarsLower by 45,173 Prior quarter: 2,546,394Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
LAZARD ASSET MANAGEMENT LLC 2,466,000 PRN28,138 dollarsUnchanged Prior quarter: 2,466,000Open filing 0001207017-26-000051 Filed 2026-11-16 Dispute this row
ARIEL INVESTMENTS, LLC Partly reported under another manager2,173,575 SH228,877,447 dollarsHigher by 112,609 Prior quarter: 2,060,966Open filing 0000936753-26-000057 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,045,810 SH215,423,793 dollarsLower by 13,768 Prior quarter: 2,059,578Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager1,822,616 SH189,460,935 dollarsLower by 443,873 Prior quarter: 2,266,489Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager1,798,599 SH189,392,475 dollarsLower by 19,587 Prior quarter: 1,818,186Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Cutler Capital Management, LLC 1,720,000 PRN1,954,006 dollarsLower by 5,000 Prior quarter: 1,725,000Open filing 0001353098-26-000006 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager1,662,797 SH175,092,524 dollarsHigher by 152,677 Prior quarter: 1,510,120Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Universal- Beteiligungs- und Servicegesellschaft mbH Partly reported under another manager1,550,000 PRN1,785,403 dollarsHigher by 450,000 Prior quarter: 1,100,000Open filing 0002057170-26-000022 Filed 2026-11-10 Dispute this row
Man Group plc Partly reported under another manager1,550,000 PRN1,765,376 dollarsUnchanged Prior quarter: 1,550,000Open filing 0001637460-26-000004 Filed 2026-11-16 Dispute this row
Jefferies Financial Group Inc. Partly reported under another manager1,498,000 PRN1,708,680 dollarsHigher by 1,011,000 Prior quarter: 487,000Open filing 0000096223-26-000034 Filed 2026-11-05 Dispute this row
T. Rowe Price Investment Management, Inc. 1,427,005 SH150,264 dollarsHigher by 325,634 Prior quarter: 1,101,371Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager1,368,265 SH144,078,252 dollarsHigher by 322,246 Prior quarter: 1,046,019Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
SHENKMAN CAPITAL MANAGEMENT INC 1,323,000 PRN1,520,632 dollarsUnchanged Prior quarter: 1,323,000Open filing 0001275228-26-000007 Filed 2026-11-10 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,279,678 SH134,750,960 dollarsLower by 305,544 Prior quarter: 1,585,222Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,245,890 SH131,214,280 dollarsLower by 41,350 Prior quarter: 1,287,240Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
UBS Group AG Partly reported under another manager1,119,167 SH117,848,286 dollarsHigher by 135,789 Prior quarter: 983,378Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager1,059,177 SH111,532 dollarsHigher by 422,380 Prior quarter: 636,797Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • MILLENNIUM MANAGEMENT LLC 15,500,000 PRN
  • ADVENT CAPITAL MANAGEMENT /DE/ 15,016,000 PRN
  • ZAZOVE ASSOCIATES LLC 12,735,000 PRN
  • Verition Fund Management LLC 10,063,000 PRN
  • READYSTATE ASSET MANAGEMENT LP 8,250,000 PRN
  • Walleye Capital LLC 8,013,000 PRN
  • CAMDEN ASSET MANAGEMENT L P /CA 3,800,000 PRN
  • CITIGROUP INC 2,495,000 PRN
  • OAKTREE CAPITAL MANAGEMENT LP 2,090,000 PRN
  • Russell Investments Group, Ltd. 971,000 PRN
  • Sixth Street Partners Management Company, L.P. 591,423 SH
  • HURRICANE CAPITAL ADVISORS LLC 500,000 PRN
  • JPMORGAN CHASE CO 472,000 PRN
  • North Peak Capital Management, LLC 343,077 SH
  • Invenomic Capital Management LP 216,217 SH
  • Jupiter Topco LLC 181,141 SH
  • Verition Fund Management LLC 105,508 SH
  • GOLDMAN SACHS GROUP INC 90,000 SH
  • GOLDMAN SACHS GROUP INC 90,000 SH
  • JUPITER ASSET MANAGEMENT LTD 69,724 SH
  • Curated Wealth Partners LLC 50,000 SH
  • Phocas Financial Corp. 43,030 SH
  • CONNORS INVESTOR SERVICES INC 42,000 SH
  • Aurora Investment Counsel 25,501 SH
  • WESBANCO BANK INC 25,500 SH
  • SG Americas Securities, LLC 25,000 PRN
  • Jupiter Research Capital (Asia) Ltd 23,450 SH
  • Jain Global LLC 14,494 SH
  • INSIGNEO ADVISORY SERVICES, LLC 14,000 PRN
  • Grandeur Peak Global Advisors, LLC 13,185 SH
  • WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 12,000 PRN
  • TWO SIGMA INVESTMENTS, LP 10,589 SH
  • Blackstone Inc. 8,268 SH
  • Robertson Stephens Wealth Management, LLC 7,939 SH
  • FOX RUN MANAGEMENT, L.L.C. 7,663 SH
  • Virtu Financial LLC 6,711 SH
  • Curi Capital, LLC 6,589 SH
  • CIM INVESTMENT MANAGEMENT INC 6,003 SH
  • Pacer Advisors, Inc. 5,108 SH
  • NATIXIS 5,000 SH
  • FIFTH THIRD BANCORP 5,000 PRN
  • COMMONWEALTH EQUITY SERVICES, LLC 4,789 SH
  • TWO SIGMA SECURITIES, LLC 4,746 SH
  • Freestone Grove Partners LP 4,737 SH
  • Aigen Investment Management, LP 3,685 SH
  • Prospera Financial Services Inc 3,495 SH
  • CAXTON ASSOCIATES LLP 3,426 SH
  • Storgate, LLC 3,383 SH
  • SG Americas Securities, LLC 3,028 SH
  • Revolve Wealth Partners, LLC 2,970 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–13 of 13

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Lois Frankel (FL21)2021-05-07Sale$1,001 - $15,0002021-05-25
Hon. Lois Frankel (FL21)2021-05-06Sale (partial)$1,001 - $15,0002021-05-25
Hon. Josh Gottheimer (NJ05)2021-01-25Sale$1,001 - $15,000JT2021-02-09
Hon. Josh Gottheimer (NJ05)2020-10-16Purchase$1,001 - $15,000JT2020-11-05
Hon. Josh Gottheimer (NJ05)2020-09-15Sale (partial)$1,001 - $15,000JT2020-10-13
Hon. Lois Frankel (FL21)2020-08-14Purchase$1,001 - $15,0002020-08-24
Hon. Gilbert Cisneros (CA39)2020-05-19Purchase$1,001 - $15,0002020-06-16
Hon. Gilbert Cisneros (CA39)2020-06-01Purchase$1,001 - $15,0002020-06-16
Hon. Josh Gottheimer (NJ05)2020-05-15Purchase$1,001 - $15,000JT2020-06-10
Hon. Josh Gottheimer (NJ05)2020-05-28Purchase$1,001 - $15,000JT2020-06-10
Hon. Lois Frankel (FL21)2018-08-07Sale$1,001 - $15,0002018-08-24
Hon. Lois Frankel (FL21)2018-06-14Sale (partial)$1,001 - $15,0002018-06-22
Hon. Lois Frankel (FL21)2018-06-07Sale (partial)$1,001 - $15,0002018-06-22

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
AQR Capital Management, LLC Common stock, $0.01 par value per share4.992,266,48906/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 1Open filing 0001167557-26-000152 Dispute this row
AQR Capital Management Holdings, LLC Common stock, $0.01 par value per share4.992,266,48906/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 1Open filing 0001167557-26-000152 Dispute this row
North Peak Capital Management, LLC Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
North Peak Capital GP, LLC Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
North Peak Capital Partners, LP Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
North Peak Capital Partners II, LP Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
North Peak Capital Alpha Fund, LP Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
North Peak Capital Ultra Fund, LP Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
Michael Kevin Kahan Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
Jeremy Steven Kahan Common stock, $.01 par value per share00.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-055541 Dispute this row
Vanguard Capital Management Common Stock5.262,445,81703/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-000608 Dispute this row
Vanguard Portfolio Management Common Stock5.592,600,14503/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100121-26-000346 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 15Open filing 0000102909-26-001482 Dispute this row
North Peak Capital Management, LLC Common stock, $.01 par value per share5.12,370,495.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
North Peak Capital GP, LLC Common stock, $.01 par value per share4.01,882,037.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
North Peak Capital Partners, LP Common stock, $.01 par value per share0.3135,354.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
North Peak Capital Partners II, LP Common stock, $.01 par value per share2.1993,566.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
North Peak Capital Alpha Fund, LP Common stock, $.01 par value per share1.4651,061.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
North Peak Capital Ultra Fund, LP Common stock, $.01 par value per share0.2102,056.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
Michael Kevin Kahan Common stock, $.01 par value per share4.01,882,037.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
Jeremy Steven Kahan Common stock, $.01 par value per share4.01,882,037.0002/24/2026 Filed 2026-03-03SCHEDULE 13GOpen filing 0001213900-26-023263 Dispute this row
AQR Capital Management, LLC Common stock, $.01 par value per share6.763,163,10412/31/2025 Filed 2026-02-13SCHEDULE 13GOpen filing 0001167557-26-000036 Dispute this row
AQR Capital Management Holdings, LLC Common stock, $.01 par value per share6.763,163,10412/31/2025 Filed 2026-02-13SCHEDULE 13GOpen filing 0001167557-26-000036 Dispute this row
Wellington Management Group LLP Common Stock4.62,203,351.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 6Open filing 0000902219-25-000328 Dispute this row
Wellington Group Holdings LLP Common Stock4.62,203,351.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 6Open filing 0000902219-25-000328 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock4.62,203,351.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 6Open filing 0000902219-25-000328 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,540,664 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020166,957
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to HAEMONETICS CORPORATION